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Abstract
Background: Cleidocranial dysplasia (CCD) is a dominantly inherited disease characterized by
hypoplastic or absent clavicles, large fontanels, dental dysplasia, and delayed skeletal development.
The purpose of this study is to investigate the genetic basis of Chinese family with CCD.
Methods: Here, a large Chinese family with CCD and hyperplastic nails was recruited. The clinical
features displayed a significant intrafamilial variation. We sequenced the coding region of the
RUNX2 gene for the mutation and phenotype analysis.
Results: The family carries a c.T407C (p.L136P) mutation in the DNA- and CBFβ-binding Runt
domain of RUNX2. Based on the crystal structure, we predict this novel missense mutation is likely
to disrupt DNA binding by RUNX2, and at least locally affect the Runt domain structure.
Conclusion: A novel missense mutation was identified in a large Chinese family with CCD with
hyperplastic nails. This report further extends the mutation spectrum and clinical features of CCD.
The identification of this mutation will facilitate prenatal diagnosis and preimplantation genetic
diagnosis.
Background
Cleidocranial dysplasia [CCD, Min 119600] is a skeletal
dysplastic disorder. Clinical features include delayed clo-
sure of skull sutures, hypoplastic or aplastic clavicles, and
dental anomalies [1]. Patients often present with wide-
open fontanels and middle face dysplasia, such as
depressed nasal bridges. Clavicular hypoplasia can cause
narrow, sloping shoulders that are often opposed at the
mid line. Other clinical features include brachydactyly,
tapering fingers, and short, broad thumbs and toes. Den-
tal malformations include delayed eruption of secondary
dentition and failure to shed primary teeth, which results
in supernumerary teeth with dental crowding and maloc-
clusion [2,3].
Published: 31 December 2007
BMC Medical Genetics 2007, 8:82 doi:10.1186/1471-2350-8-82
Received: 9 August 2007
Accepted: 31 December 2007
This article is available from: http://www.biomedcentral.com/1471-2350/8/82
© 2007 Tang et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genetics 2007, 8:82 http://www.biomedcentral.com/1471-2350/8/82
Page 2 of 6
(page number not for citation purposes)
A variety of mutations in RUNX2 cause CCD [4-11], but
no clear genotype-phenotype correlation has been estab-
lished in CCD patients [8]. RUNX2 is an osteoblast-spe-
cific transcription factor that is a member of the core
binding family (CBF) [12]. RUNX2 interacts with a non
DNA-binding CBFβ subunit and the resulting complex
binds to cis-acting elements in the promoters of genes
required for skeletal formation such as osteocalcin [13].
The RUNX2-CBFβ complex serves as a master regulator of
osteoblast differentiation and a scaffold that controls the
assembly of transcription factors regulating skeletal gene
expression [14]. In addition to osteocalcin, RUNX2 regu-
lates vascular endothelial growth factor (VEGF) [15],
COL10A1, and matrix metalloproteinase 13 (MMP13)
[16]. COL10A1 is crucial for chondrocyte hypertrophy.
VEGF and MMP13 are critical for hypertrophic chondro-
cytes, and mutations in RUNX2 result in a markedly
diminished hypertrophic zone in long bone cartilage [17].
Additionally, RUNX2 and phosphatidylinositol 3-kinase
(PI3K) regulate osteoblast and chondrocyte differentia-
tion and migration in a mutually dependent manner [18].
Signal transducer and activator of transcription 1(STAT1)
also interacts with RUNX2 and attenuates its transcrip-
tional activity through cytoplasmic sequestration [19]. It
has been shown that overexpression of RUNX2 results in
growth arrest through p27 (KIP1)-induced inhibition of
the s-phase cyclin complex, followed by dephosphoryla-
tion of the RB1 protein [20]. Since osteoblast proliferation
and differentiation are inversely correlated, RUNX2 inhib-
its osteoblast proliferation. Here, we report a large Chi-
nese family with CCD. We predict that a novel mutation
of RUNX2 disrupts the protein-DNA interaction.
Methods
Patients
The pedigree is shown in Figure 1. The proband (II-7) is a
34-year-old G3P1 female. She received medical attention
for her polyhydramnia and short stature. Upon physical
examination, her height was 141.5 cm, weight 60 kg, and
her arm span was 146.5 cm. She had an asymmetric face,
a bossing of the forehead, hypertelorism, a depressed
nasal bridge, malocclusion of teeth, a prominent lower
jaw, sloping shoulders, and hyperplastic fingernails and
toenails. X-ray analysis showed wormian bones and poor
pneumatization of the sinuses (Figure 2A); her right cus-
pid tooth had not erupted and was hypoplastic. A chest x-
ray revealed a cone-shaped chest, high scapular bones,
aplasia of lateral and middle third of the clavicle, mild
scoliosis between T6 and T10 (Figure 2B), and mild dislo-
cation of vertebrae between L5-S1 (Figure 2C), a widening
sacroiliac joint, a wide pubic symphysis, hypoplastic
pubic bones (Figure 2D), normal hips. The knee and hand
x-rays were normal. The family history shows that there
are 11 affected individuals (6 males, 5 females) (Figure 1)
from a total of 28 individuals in the family. All affected
individuals have short statue, but other clinical features
are very variable (Table 1). For example, several affected
individuals have a normal clavicle. The cranial facial fea-
tures ranged from macrocephaly to severely depressed
anterior fontanels. The most striking feature of this family
is that all affected individuals have hyperplastic nails (Fig-
ure 3) which is not seen in unaffected family members,
and has not been previously described in CCD patients.
Genetic analysis
Informed consent was obtained in accordance with a pro-
tocol approved by the Wenzhou 2nd  People Hospital
Human Subject Review Board. 3 ml of blood was drawn
and stored in EDTA anticoagulation tubes. Genomic DNA
was purified with a genomic DNA purification kit (version
3.0, Baosheng Company, Daling, China). Genomic DNA
was PCR-amplified as previously described. Eight sets of
exon-specific primers were used to amplify the RUNX2
coding region [6]. The primers correspond to intron
sequences, typically 30 to 50 bp away from the exon-
intron boundary.
PCR was carried out using a PCR kit, following the manu-
facturer's instructions (Baosheng Company, Daling,
China). The genomic DNA was first denatured at 94°C for
3 minutes, followed by 32 cycles of 94°C for 20 seconds,
50°C to 60°C for 30 seconds, and 72°C for 30 seconds.
Table 1: Clinical Manifestation of Family with CCD
Patient Sex Age Height (cm) Cranial Shoulders Clavicle Nails Other
I1 F 76 very short frontal bossing sloping, bilateral elevated nail bed
II2 F 52 140.0 increased suture space severe sloping, bilateral elevated nail bed
II3 M 49 150.5 depressed anterior fontanels severe sloping, bilateral absence of lateral 1/3, bilateral elevated nail bed
II6 M 40 152.0 frontal bossing mild sloping, bilateral absence of lateral 1/3, right elevated nail bed
II7 F 34 141.5 frontal bossing mild sloping, bilateral absence of lateral 1/3, right elevated nail bed normal ALP
III2 M 33 155.0 increased suture space severe sloping, bilateral absence of lateral 1/3, bilateral elevated nail bed
III4 F 26 134.5 severe depressed anterior fontanels Sloping, bilateral elevated nail bed normal ALP
III12 F 12 120.5 frontal bossing Sloping, bilateral normal elevated nail bed
III14 M 3 80.0 frontal bossing increased mobility, Bilateral normal elevated nail bed
IV2 M 4 90.0 macrocephaly increased mobility, Bilateral normal elevated nail bed
IV3 M 2 83.5 macrocephaly increased mobility, Bilateral absence of lateral 1/3, right elevated nail bedBMC Medical Genetics 2007, 8:82 http://www.biomedcentral.com/1471-2350/8/82
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The PCR products were extended at 72°C for 5 minutes.
The products were gel-purified with an agrose gel DNA
purification kit, version 2.0 (Baosheng Company, Daling,
China), and the purified PCR products sequenced using
the forward and reverse primers. The sequences were ana-
lyzed with DNAStar.
Results
We detected a single base-pair variant in exon 1 that was
verified by sequencing both strands (Figure 4). This vari-
ant in the cDNA at position 407 results in the substitution
of leucine 136 with proline (Left panel). It co-segregates
with affected individuals of the family. There is no such a
sequence variant at that position in unaffected individuals
(Right panel). More than 200 population-matched chro-
mosomes were sequenced and no sequence variations
were detected, suggesting that the sequence aberration is
A, Finger nails of II-7, B, Toe nail, II-12 and C, Finger nail, I-1 Figure 3
A, Finger nails of II-7, B, Toe nail, II-12 and C, Finger nail, I-1.
A) Cranial x-ray showing an asymmetrical skull, abnormal  wormian bone, poor pneumatization of the sinuses, no erup- tion of third teeth, and a hypoplastic third tooth of the right  upper jaw Figure 2
A) Cranial x-ray showing an asymmetrical skull, abnormal 
wormian bone, poor pneumatization of the sinuses, no erup-
tion of third teeth, and a hypoplastic third tooth of the right 
upper jaw. B) Chest x-ray reveals a cone-shaped chest, high 
position of the scapular bone, aplasia of the lateral and mid-
dle thirds of the clavicle, and mild scoliosis between T6–T10. 
C) Vertebral x-ray showing mild dislocation of L5/S1. D) Pel-
vic x-ray showing a widening sacroiliac joint, wide pubic sym-
physis, hypoplastic pubic bone and normal hips.
Pedigree of CCD family with hyperplastic nails Figure 1
Pedigree of CCD family with hyperplastic nails. The proband (II7) is indicated by an arrow. Squares indicate males and circles 
indicate females. Closed symbols indicate affected individuals, and crossed lines denote deceased individuals.BMC Medical Genetics 2007, 8:82 http://www.biomedcentral.com/1471-2350/8/82
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pathogenic. A leucine at that position is conserved in the
Runt domain proteins of all vertebrates, suggesting it is
functionally important (Figure 5A). The analogous resi-
due in RUNX1 is L85, which in the crystal structures of the
highly conserved RUNX1 Runt domain-CBFβ-DNA ter-
nary complex is located in the βA'-B loop [21]. Two adja-
cent residues in the βA'-B loop, R131 and K134 are
predicted to directly contact the DNA based on the
RUNX1 structure (Figure 5B). The L136 side chain is ori-
ented away from the DNA interface. Substitution of L136
with proline is predicted to alter the structure of the DNA-
binding βA'-B loop, and thereby impair DNA binding by
RUNX2. Several mutations at the DNA binding interface
in RUNX1 were shown to also affect binding of CBFβ to
the opposite side of the Runt domain because of their
overall effect on the Runt domain structure [22] (Matheny
CJ et al, unpublished data). One of these mutations was
R80C, which is also located in the RUNX1 βA'-B loop
(corresponding to R131 in RUNX2). Therefore, it is possi-
ble that the L136P mutation in RUNX2 would also affect
CBFβ binding, but this was not directly tested.
Discussion
Thus far, more than 70 mutations have been identified in
the RUNX2 gene. The mutations are clustered in the Runt
domain but occur throughout the RUNX2 protein.
RUNX2 binds to DNA in a sequence-specific manner and
CBFβ enhances its DNA binding affinity. Here, we identi-
fied a novel missense mutation in the Runt domain in a
large Chinese family. Clinically, all affected individuals
have hyperplastic nails. We show for the first time an unu-
sual phenotype, hyperplastic nails, the molecular basis of
which is unknown. This additional phenotype is most
likely caused by RUNX2 mutation. However, we cannot
rule out the possibility that another genetic alternation is
co-segregated with the RUNX2 gene and associated with
this phenotype. The most likely mechanism by which the
L136P mutation affects RUNX2 function is through
impaired DNA binding caused by structural alterations in
the DNA-binding βA'-B loop. The identification of the
L136P mutation in this family further expands the clinical
phenotypes and mutation spectrum, and will contribute
to prenatal molecular diagnosis and preimplantation
genetic diagnoses.
Thus far, genotype-phenotype correlations have not been
established for the different RUNX2 mutations found in
CCD, although Zhou et al.[11] suggested that a T200A
mutation found in a family with mild CCD might be a
hypomorphic mutation. The hypomorphic nature of the
T200A mutation was recently confirmed in mice [11]
(Matheny CJ et al, unpublished data). There is variable
expressivity of RUNX2 CCD mutations. For example, in
one Italian family with a RUNX2 mutation, the reported
clinical features ranged from minimal or absent clavicle to
the presence of hypoplastic clavicles and delayed closure
of the anterior fontanel in addition to classic craniofacial
features. The family we describe here also displays signifi-
cant intrafamilial phenotypic variation, indicating that
Sequencing traces showing the missense mutation in  c.T407C, which causes a change from leucine to proline at  amino acid 136 (p.L136P) Figure 4
Sequencing traces showing the missense mutation in 
c.T407C, which causes a change from leucine to proline at 
amino acid 136 (p.L136P).
A) Comparison of sequences in the vicinity of RUNX2 L136  (arrow) from various species Figure 5
A) Comparison of sequences in the vicinity of RUNX2 L136 
(arrow) from various species. B) The RUNX1 Runt domain-
CBFβ-DNA complex showing the location of L136 (green). 
The Runt domain is grey, CBFβ is purple, and the DNA is 
yellow and orange. Side chains of the DNA contacting resi-
dues R131 and K134 in the βA'-B loop are also shown.BMC Medical Genetics 2007, 8:82 http://www.biomedcentral.com/1471-2350/8/82
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there are modifying alleles at other loci. It is uncommon
for CCD patients to display clinical features other than
skeletal abnormalities. Two Italian CCD patients were
reported to exhibit shoulder muscle abnormalities [23].
Quack et al. reported that an R225Q mutation affects
nuclear RUNX2 accumulation and results exclusively in
dental phenotypes. One patient with mutations resulting
in an amino acid substitution at position 702 in
sequences C-terminal to the Runt domain had osteoporo-
sis, suggesting that RUNX2 not only functions in skeletal
development, but also in maintaining adult bone density
[6]. Extensive mutagenesis experiments have shown that
many RUNX2 mutations impair DNA binding, while oth-
ers affect CBFβ binding or the Runt domain structure
[9,11,21,24-29] (Matheny CJ et al., unpublished data).
Conclusion
L136P is a novel mutation that most likely interferes with
DNA binding by RUNX2 and would result in a nonfunc-
tional or strongly hypomorphic allele.
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